A Phase II, Randomized, Double-blind, Controlled Study to Evaluate the Immune Responses, Safety and Clinical Efficacy of Three Doses of Neovacs' TNF-Kinoid in Adult Patients With Rheumatoid Arthritis Who Have Relapsed Despite Anti-TNFα Biological Therapy.

Trial Profile

A Phase II, Randomized, Double-blind, Controlled Study to Evaluate the Immune Responses, Safety and Clinical Efficacy of Three Doses of Neovacs' TNF-Kinoid in Adult Patients With Rheumatoid Arthritis Who Have Relapsed Despite Anti-TNFα Biological Therapy.

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Sep 2014

At a glance

  • Drugs Tumour necrosis factor-alpha kinoid (Primary)
  • Indications Rheumatoid arthritis
  • Focus Pharmacodynamics
  • Sponsors Neovacs
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 14 Nov 2012 Results presented at the 76th Annual Scientific Meeting of the American College of Rheumatology and the 47th Annual Meeting of the Association of Rheumatology and Health Professionals.
    • 13 Nov 2012 6-Month results were presented at the Annual Meeting of the American College of Rheumatology (ACR) in November 2012, according to a Neovacs media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top